Sacituzumab
- Generic Name
- Sacituzumab
Drug Screening Using IMD in Bladder Cancer
Early Phase 1
Not yet recruiting
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Device: Implantable Micro-DeviceDrug: Gemcitabine/Cisplatin IDrug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/AvelumabDrug: Gemcitabine/Cisplatin IIDrug: Gemcitabine/CarboplatinDrug: Methotrexate/Vinblastine/Doxorubicin/CisplatinDrug: Gemcitabine/Cisplatin/NivolumabDrug: Paclitaxel/Docetaxel/IfosfamideDrug: Gemcitabine/Carboplatin/Nivolumab
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06204614
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Phase 1
Recruiting
- Conditions
- Ovarian CancerMalignant Neoplasm of Uterus
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 54
- Registration Number
- NCT06040970
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath